In Search of the Fountain of Youth Healthy Aging | Maximum Wellness – WWLTV.com

Aging, which is associated with a decline in an individuals physical and physiological capabilities, is part of life as in death and taxes.

NEW ORLEANS Based on research Calorie Restriction and Aging in Humans which appeared online in June of 2020 in the Annual Review of Nutrition over the past century, the average life span in higher- and lower-income countries has increased by 15 and 30 years, respectively.

Additionally, this (outcome) is the result of lessening mortality and morbidity from food shortage, malnutrition, and infectious diseases through improved food supply and quality, as well as, advances in health care.

Aging, which is associated with a decline in an individuals physical and physiological capabilities, is part of life as in death and taxes.

The speed and progression of age can be effected by such variables, as excess food consumption overweight and obesity, poor fitness less than 150 minutes of light to moderate weekly exercise, 75 minutes of moderate to vigorous weekly exercise, or a combination of both, or, the extent of an individuals exposure to disease all equaling secondary aging, added to or subtracted from (with prevention in place) the normal primary aging process.

According to the Annual Nutrition Reviews researchers from Pennington Biomedical Research Center, Louisiana State University, and Nutrition and Movement Sciences at Maastricht University in the Netherlands, advanced age is associated with increased mortality and susceptibility to disease. This increase is caused by a progressive decline in physiological function. The slope of this decline over time can be defined as aging, which, under an optimal scenario, may approach 120 years.

Primary aging, note the researchers, describes the inevitable age-associated decline in physiological and physical functions due to energy expenditure and oxidative stress. It appears that individuals with higher metabolic rates have shorter life spans - known as the rate-of-living theory - which the Pennington and Maastricht researchers say is, still a matter of discussion, and may only apply in species, and not between species.

It was also noted that average lifespan is reduced to 61 to 83 years an acceleration of this process reflects the interaction between innate aging and the extrinsic influences of the environment.

As aging applies to our functional capacity, Ive often commented to many of my athlete clients when my patience (with age) wears thin - discussing my strategic plan that age is mandatory, but maturity is optional.

Theyve also heard me explain from day one that my objective is to make them perform better than before with a higher quality of health in the years extending beyond their playing career.

I recognize three ages chronological age, what were given at birth, performance age, how successful we are at achieving our mental and physical objectives on and off the playing field, and health age, resistance to the effects of chronic fatigue and disease.

With the exception of our chronological age, being the constant, the goal from a health age perspective is to work toward a compressed morbidity, pushing illness to the shortest period of time late in life which is extended toward a higher quality.

The pillars of life extension slowing the aging process has to do with lengthening the telomeres - segments of DNA occurring at the ends of the chromosomes in eukaryotic cells (that containing a clearly defined nucleus), according to Britannica.com.

Notes the website, once telomeres have been reduced to a certain size, the cell reaches a crisis point and is prevented from dividing further. As a consequence, the cell dies. Thus, the processes of cell aging and cell death are regulated in part by telomeres.

Calorie restriction (CR) has been shown to increase life span from 1 to 5 years in animal studies - with some human support. However, for those over 60, the potential increase in life span may be offset by the potential for loss of lean muscle mass in light of sarcopenia the aging loss of muscle. Daily protein intake may need to increase from 0.8 grams per kilogram of body weight to 1.2 grams.

The nutrient resveratrol, found in red grape skins, peanuts, red wine, and in supplement form has been demonstrated to mimic CR, but the optimum dosage and administration is still being investigated.

The key to living a healthier, longer life is to practice healthy eating the Mediterranean eating style, exercise using the guidelines outlined earlier in this

column, stress control opting for meditation, controlled breathing, even prayer, laughing, associating with friends, giving and receiving love human or pet, and common sense during troubling times. Its not that hard.

Add, a dose of passion a life force that allows you to reinvent yourself on a daily basis, and you place yourself on the path toward the elisive fountain of youth.

Sign up for Mackie Mail, on mackieshilstone.com - my free, weekly wellness update with Fitness in Small Spaces 90-second videos Monday, my Maximum Wellness podcast and script on Wednesday, and, on Friday you receive my WWL/WUPL 3-minute Workout Wednesday segment. You can also contact spencer@mackienutrition.com should you desire nutrition product shipped or locally delivered to your door. My 4 locally operated GNC franchise stores are open, regularly sanitized with appropriate staff and customer safety in place. Check mackieshilstone.com for store locations and hours.

Get breaking news from your neighborhood delivered directly to you by downloading the new FREE WWL-TV News app now in theIOS App StoreorGoogle Play.

Stay up-to-date with the latest news and weather in the New Orleans area on the all-new free WWL TV app. Our app features the latest breaking news that impacts you and your family, interactive weather and radar, and live video from our newscasts and local events. LOCAL & BREAKING NEWS * Receive r...

See original here:
In Search of the Fountain of Youth Healthy Aging | Maximum Wellness - WWLTV.com

From Weight Gain To Digestive Issue, Know All Harmful Effects Of Sleep Deprivation On Your Body – Doctor NDTV

Sleep deprivation is linked with a higher risk of heart disease. it can negatively affect your heath in various ways. Here are some ill-effects of sleep deprivation on your different body parts.

Poor sleep can make you gain weight

Lack of sleep makes you grumpy. It can lead to constant fatigue and make it difficult to complete day to day tasks efficiently. The ill-effects of poor sleep are not limited to just mood. It can negatively affect your different body organs and body processes. Sleeplessness is also linked with a higher risk of several chronic diseases. A healthy sleeping pattern promotes overall health. It ensures optimum energy levels and supports the functioning of different body organs. If you are spending too much time on your phone at night or facing difficulty to fall asleep, then you must understand the harmful effect of poor sleep schedule on your body.

Too less sleep can affect your brain and memory too. You may find difficulty in concentrating. You may face difficulty in learning new things. Poor sleep schedule affects your mood and memory both. Studies also suggest that lack of sleep can worsen the symptoms of depression, anxiety and other mental health issues.

Lack of sleep can affect your moodPhoto Credit: iStock

A strong immune system protects you against several diseases. Your sleeping pattern may affect your immunity too. Ensure better sleep to keep your immune system healthy.

Also read:Nutritionist Explains How Stress Affects Immunity And What You Can Do About It

Lack of sleep causes hormonal changes. These can make you consume more calories than usual leading to weight gain. Enough sleep can help you beat those cravings.

Lack of sleep can also lead to digestive issues. It can result in cravings for unhealthy foods and you may also consume more calories than required. Lack of energy can make you skip exercising too. These factors can lead to digestive issues.

Sleep deprivation could be the reason behind your digestive issuesPhoto Credit: iStock

Insufficient sleep can trigger various risk factors that put you at a higher risk of heart disease. It can increase the risk of high blood pressure, diabetes, inflammation and obesity. These are some of the major risk factors for heart disease.

Promoted

Also read: Ways to fight insomnia

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

Read more:
From Weight Gain To Digestive Issue, Know All Harmful Effects Of Sleep Deprivation On Your Body - Doctor NDTV

Keep Your Lungs Healthy With These Simple Methods – NDTV Doctor

Lung health: There are various factors that can negatively affect your lung health including lifestyle and environmental factors. To keep your lungs healthy you need to follow certain preventive measures. Read here to know how.

Regular exercise can help you keep your lungs healthy

Lungs are the centre of the respiratory system. You need healthy lungs for lifetime. But many fail to take proper care lungs. The truth is you need to take care of your lungs just like your physical health or other organs. There is a wide variety of lung diseases that can affect an individual. Some of these are- chronic obstructive pulmonary disease (COPD), chronic bronchitis, pneumonia, asthma, tuberculosis, lung cancer and more. There are various factors that can negatively affect your lung health including both lifestyle and environmental factors. To keep your lungs healthy you need to follow certain preventive measures. Read on to know some of these.

Smoke is your lungs' enemy. It can affect your lungs negatively and trigger the risk of several lung diseases. Not just direct smoking, exposure to second-hand smoke is also alarmingly dangerous. You should quit smoking not just for yourself but for your loved one too. Promoting a smoke-free environment is beneficial for your overall health too.

A smoke-free life can promote healthy lungsPhoto Credit: iStock

Breathing exercises can make your lungs work efficiently. These will help you inhale ad exhale in a specific pattern. Breathing deeply will fill your lung with oxygen and boost the functioning of the lungs. You can start your day with breathing exercises. It will hardly take a few minutes and offer you other health benefits too like controlled stress and better mental health.

Deep breathing can help boost lung healthPhoto Credit: iStock

Pollutants are also toxic to your lung health. Increased pollution these days can take a toll on your lung health. Avoid visiting places with high pollution levels. Also, wear a mask when pollution levels are high.

Not just outdoors, indoors are also loaded with pollutants too. Clean more often to keep indoors safe.

Also read:Chronic Lung Disease: 6 Most Effective Home Remedies

Promoted

Also read: Ways to quit smoking

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

Originally posted here:
Keep Your Lungs Healthy With These Simple Methods - NDTV Doctor

Health and wellness: Finding a new normal Jasper’s source for news, sports, arts, culture, and more – the fitzhugh

For information about healthy living for families during COVID-19, visit ahs.ca/healthytogether.

Life in Alberta has been turned upside down with the COVID-19 outbreak.

As our province takes its first steps to recovery, many of us ask if normal will ever return.

With the answer unclear, your family may need to find a new normal. These tips can help you to weather these uncertain times.

Find a New Routine

Schools are out for the summer. Many other public facilities remain closed. Countless moms and dads are juggling to keep up and keep their children safe. Nearly every family in Alberta has had their daily routines disrupted.

Planning and following routines can lend a sense of order to these topsy-turvy times, especially for children.

Farah Bandali, Alberta Health Services director of Healthy Children and Families with Healthy

Living said: Routines can help you and children feel more comfortable during times of uncertainty.

Day-to-day routines add structure to family life and reflect whats important to your family. Theyre also a way to let your kids know what to expect during the day.

Wake up times, bedtimes, meals and snacks, play, walks and quiet time. All are examples of what you can weave into your familys routine.

Bring On the Laughter

Tell a corny joke. Have a staring contest. Tickle one another. Tell a goofy story.

Science America says laughter and appreciation of humour are vital components of adaptive social, emotional and cognitive function Laughter is, after all, a communal activity which promotes bonding, diffuses potential conflict and eases stress and anxiety.

Thats a fancy-schmancy way of saying laughter brings people together and helps us think. It also helps us express our feelings, can turn a tense moment into a light moment and is just plain good for us.

Remember the Basics

In tough times, we can lose track of the basics of healthy living.

Heres a friendly reminder: eat healthy foods as much as possible. Stay connected with other family members, friends and co-workers while maintaining physical distancing. Get a good nights sleep.

Most of all, reach out for help if you need it. Alberta Health Services, the Government of Alberta, the Government of Canada, your local municipality and hundreds of community groups have all kinds of support and assistance for Albertans.

For information about healthy living for families during COVID-19, visit ahs.ca/healthytogether.

This wellness article was provided by Alberta Health Services.

In response to the COVID-19 crisis, Fitzhugh is now soliciting donations from readers. This program is designed to support our local journalism in a time where our advertisers are unable to due to their own economic constraints. Fitzhugh has always been a free product and will continue to be free. This is a means for those who can afford to support local media to help ensure those who cant afford to can get access to trusted local information. You can make a one-time or a monthly donation of any amount and cancel at any time.

Click on https://support.fitzhugh.ca for more information or to make your donation.

Thank you in advance for your support.

Read more:
Health and wellness: Finding a new normal Jasper's source for news, sports, arts, culture, and more - the fitzhugh

3 Healthy Habits That Can Help You Live Longer – News18

For a long time now, humans have been looking for the secret to a long and healthy life. Some say it's all about genetics and some associate it with better availability of healthcare facilities. Sure, it is possible for some to be genetically gifted to have a longer life. But genes dont play as huge a role in longevity as your environment and lifestyle.

Studies have shown that people who live more than 100 years have various things in common, the top amongst them being their healthy lifestyle and their positive outlook towards life.

Here are 3 secrets to living a healthy and long life from centenarians (those who have lived beyond 100 years):

1. A healthy diet

A healthy and balanced diet is undoubtedly one of the keys to good health. Experts suggest that a balanced diet should have 7 components - carbs, proteins, unsaturated fats, fibre, vitamins, minerals and water. Water plays a role in various metabolic activities in the body. Make sure you drink at least 8-10 glasses of water a day.

Avoid overeating at all costs since it would promote obesity, which may further increase your risk of various chronic diseases. Instead, follow caloric restriction whenever possible. Caloric restriction is an excellent way to promote longevity. Various studies show the benefits of caloric restriction on health, including one done in Japan that showed how lifetime caloric restriction reduces the risk of diseases and increases lifespan. It can also help you reduce weight.

It is important to note that the term overeating may not mean the same for everyone. Overeating means eating more calories than you need in a day. Daily calorie requirement for different people varies as per their age, sex and physical activity levels. Long term caloric restriction may cause a constant feeling of hunger and low body temperature. So, it is best to talk to a dietician if you are thinking of trying it.

2. Workout regularly

Regular physical activity keeps up your muscle strength, improves your immune system and reduces your risk of chronic diseases including diabetes, heart diseases and cancer. It also improves memory and cognition and can reduce depression and elevate mood.

Experts suggest doing at least 30 minutes of moderate to vigorous activity daily to keep up your health.

However, like every good thing, over-exercising may do more harm than good, especially if you have a health condition. Also, if you dont generally work out, dont jump into the deep end and instead start slowly with a 5-10 minute routine first. Increase the duration and intensity gradually.

3. Be positive

A positive outlook can do miracles for both your mental and physical health. It reduces depression and the risk of diseases. A 35-year-long study done in the USA showed a direct connection between optimism and mortality rate.

On the other hand, stress and anxiety can trigger various pathological conditions. Try and practice mindfulness, breathing exercises and meditation to help reduce stress. Dont hesitate to reach out to your friends and family if you need help

For more information, read our article onBalanced diet chart.

Health articles on News18 are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Follow @News18Lifestyle for more

The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor News18 is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.

Go here to see the original:
3 Healthy Habits That Can Help You Live Longer - News18

How NFL offensive linemen escape the 5,000-calorie lunch and transform in retirement – ESPN

Jul 6, 2020

Emily KaplanESPN

It's 3 p.m., and Joe Thomas needs to eat. He's driving with his family but is getting hungry. Is it really hunger? He doesn't know. Throughout his entire NFL career as an offensive tackle with the Cleveland Browns, Thomas was conditioned to eat every two hours, because his job literally depended on it.

Thomas finds a McDonald's on the GPS. It will be quick -- just a bit of fuel between lunch and dinner. He orders two double cheeseburgers, two McChickens, a double quarter-pounder with cheese, one large order of fries and a large Dr. Pepper.

"Or another sugary drink," he said recently. "Just to add 500 calories, the easy way."

2 Related

It wasn't easy playing 10,000 consecutive snaps or fending off football's most explosive pass-rushers. But it was just as hard for Thomas to maintain a 300-plus-pound frame. He had to consume an insatiable amount of food. Here's a potential day in the life:

Think breakfast: four pieces of bacon, four sausage links, eight eggs, three pancakes and oatmeal with peanut butter, followed by a midmorning protein shake.

Lunch? Perhaps pasta, meatballs, cookies "and maybe a salad, great, whatever" from the team cafeteria.

For dinner, Thomas could devour an entire Detroit-style pizza himself, and then follow it with a sleeve of Thin Mint Girl Scout cookies and a bowl of ice cream. And finally, he would slurp down another protein shake before getting into bed.

"If I went two hours without eating, I literally would have cut your arm off and started eating it," the former offensive lineman said. "I felt if I missed a meal after two hours, I was going to lose weight, and I was going to get in trouble. That was the mindset I had. We got weighed in on Mondays, and if I lost 5 pounds, my coach was going to give me hell."

Eating in excess isn't as glamorous as it sounds. In fact, laborious might be the better word. Throughout his career, Thomas woke up in the middle of the night and "crushed Tums." He relied on pain medications and anti-inflammatories, and he had constant heartburn.

Then Thomas retired in 2018. "When you start eating and exercising like a normal human being," Thomas said, "the health benefits are amazing." He not only threw away the over-the-counter meds, but his skin cleared up, his yoga practice improved and he felt less bloated. Within six months, 60 pounds melted off from his 325-pound playing weight. By September 2019, TMZ picked up Thomas' transformation, headlining an article: "Ex-NFL Fat Guy ... LOOKS LIKE A CHISELED GREEK GOD."

"I just had a great laugh," Thomas said. "Isn't that the typical lineman life? Eleven years in the NFL, and all I'm known as now is ex-NFL fat guy."

Thomas is the latest example of an offensive lineman who, after retiring, recommitted to a normalized, healthy lifestyle after overeating and over-medicating during his NFL career. His journey might seem dramatic, but it's not uncommon.

Longtime San Francisco 49ers tackle Joe Staley, who played in the most recent Super Bowl, has already donated five garbage bags of clothing and bought all new belts since his waist slimmed from 40 to 36 inches and he lost 50 pounds. Former Baltimore Ravens guard Marshal Yanda dropped 60 pounds in three months by going from 6,000 calories per day to 2,000. Nick Hardwick, Jeff Saturday, Alan Faneca and Matt Birk are all former big guys who now look like shells of themselves, which generated tabloid-like attention. The list continues on and on.

So how'd they pull it off? We interviewed nine retired offensive linemen about the lengths they went to in bulking up and their secrets to slimming down after hanging up their cleats. The players were candid about body image insecurities, outrageous diets, struggles with eating disorders and the short- and long-term health ramifications of maintaining their playing weights for so many years.

Former offensive tackle Jordan Gross started 167 games over 11 seasons for the Carolina Panthers. He was a Pro Bowler three times, made the All-Rookie team in 2003 and started at right tackle for the Panthers in Super Bowl XXXVIII. Then he retired in 2014 and lost 70 pounds within six months.

"Fans know me more for losing weight than they do for anything I did in my entire career," Gross said.

Big questions | Power Rankings Free agency: Tracker | Grades Draft: All 255 picks | Grades Fantasy: Cheat sheets | Projections 2020 schedule | More NFL coverage

Although that kind of weight loss can be inspiring, it also points to the unhealthy relationship with food many offensive linemen develop, usually dating back to college. Faneca, a first-round draft pick of the Pittsburgh Steelers in 1998 who went on to 201 career starts with three teams, recalls his position coach at LSU chastising the entire offensive line once for "looking like a bunch of stuffed sausages," challenging them to lose a pound a day. Later, he was told he had to gain more.

Thomas puts it bluntly: "You're training yourself to have an eating disorder the way you view food when you're in the NFL, and to try to deprogram that is a real challenge." Body image and self-esteem issues can fester, as these athletes are told their worth can essentially be measured in calories and pounds.

"I always had this insecurity of being big when it came to dating life, talking to women and going out being a 300-pound man," said former Tampa Bay Buccaneers and Atlanta Falcons center/guard Joe Hawley. "I didn't want to be that big, but I had to because I loved football and that was my job."

A lot of the weight is artificial to begin with. As Gross points out, "not many people are naturally that big," but bulking up was essential to playing at the highest level and making millions of dollars. Gross, for example, ingested an enormous amount of protein each day while playing, including six pieces of bacon, six scrambled eggs, two 50-gram protein shakes, four hard-boiled eggs and two chicken breasts -- all before 2 p.m. in the afternoon.

It's a somewhat new phenomenon, according to Dr. Archie Roberts, a 1965 draft pick of the Jets who went on to become a cardiac surgeon. In 2001, Roberts co-founded the Living Heart Foundation, which annually conducts health screenings for retired football players. "In the 1990s, there was a push that suggested to some people that putting on more weight might make it a more effective and exciting game," Roberts said. "Because the bigger offensive linemen could hold off the defensive rush for a longer time so that the quarterback could throw the ball down the field, leading to more spectacular passing plays."

Playing weights began ballooning across the league, especially on the line. According to Elias Sports Bureau research, the average weight of starting offensive linemen was 254.3 pounds in 1970. It jumped to 276.9 by 1990, but the largest increase in poundage would come in the following 10 years. A decade later, the average O-line starter checked in at 309.4 pounds. Today the number stands at 315, more than 60 pounds heavier than 50 years ago.

Hawley typically played between 295 and 300 pounds, but during his fifth year in the league, he adopted the paleo diet and ate clean. He lost 10 to 15 pounds and played the following season at 285. "It was hard to keep weight on eating clean like that, but I felt so much better," Hawley said. "I had so much energy; I wasn't as lethargic."

Then, he re-signed in Tampa Bay.

"Because I was getting pushed around a little bit playing on the offensive line that way, they told me I needed to gain weight," Hawley said. "So I went to a more unhealthy diet, which made me feel, well, not as good. But it's what I had to do to play."

"Being skinny as a lineman wouldn't be helpful, because you would have to create more force to stop those big guys," Thomas said. "Inertia becomes an issue. I'm a big, fat guy, you're running at me, you don't have to create as much force because I'm just heavier, fatter and have more mass."

Although that mass helps on the field, health complications can follow. In May, USA Today ran an entire column wondering if offensive linemen were more susceptible to severe complications from COVID-19 because of their size. Roberts warns that massive weight gain can also lead to obesity. "Which then affects their heart, lungs, kidney and their minds," Roberts said. "It's not proven, but it also may be associated with Alzheimer's disease and possibly traumatic brain injury."

Once playing careers wind down, many players must assess whether it's worth it to carry the extra pounds. Many have decided to downsize.

Faneca, the longtime Steelers guard, remembers the day he hit a milestone of losing 30 pounds. He was playing on the floor with his daughter and he got up without having to "do the old-man grunt." "I just stood up, no problem," Faneca said. "And I was like, 'Wow, this is nice.'"

Early rankings: Kiper | McShay Meet the QBs | Lawrence v. Burrow Predicting risers, sleepers, more Projecting the top 10 picks for 2021 More NFL draft coverage

Thomas said when he was 300 pounds, his body would ache if he had to stand for a few minutes. Gross said he hated the sweating. "I would just sweat profusely all the time," he lamented. "My wife would have hypothermia from me having the room so cold all the time."

Hardwick, a center with the then-San Diego Chargers who maxed out at 308, said his initial motivation to lose weight was to relieve pressure from his body. (According to the April issue of the Harvard Medical School newsletter, each additional pound you carry places about 4 pounds of stress on the knee joints.)

"But then there's this material aspect to it," Hardwick said. "You want to be able to wear cooler clothes, and go into stores and start shopping off the rack. And that's alluring for a while. Then that wears off, and you settle in, and people stop freaking out every time they see you. And you just become comfortable once again in your own skin."

Staley, albeit sheepishly, admits he likes the fact that his muscles are getting defined.

"As an offensive lineman, you're always known as this big, humongous, unathletic blob," Staley said. "Offensive linemen get casted in a movie, and they're always 500 pounds. Then you get the opportunity to be healthy again, and all of the effort you used to put into football, you put into that. It gives you a focus once you retire. It's a little bit vain, but I'm starting to see abs that I've always wanted. And it's kind of exciting."

There are two types of offensive linemen: those who must artificially add the pounds on, and those who are naturally big.

"I'm the latter," said Damien Woody, a longtime NFL lineman and current ESPN analyst. "I could literally breathe and inhale and gain 5 pounds." During a summer growth spurt after his sophomore year of high school, Woody grew 6 inches and gained 70 pounds. By the time he got to Boston College, he already weighed 300. "It was never a problem for me to put weight on," he said.

The other group? Gaining weight can become an all-consuming sport, which often begins in the collegiate years. Consider Hardwick, who wrestled in the 171-pound weight class in high school. He enrolled at Purdue on a ROTC scholarship, got a tryout for the football team and ballooned to 295 by slathering 2 pounds of ground beef on multiple tortillas at dinner. Hardwick also downed a 600- or 700-calorie protein shake before bed and set his alarm to drink a similar one at 3 a.m.

At this year's NFL combine, Ben Bartch was a topic of conversation after talking about his go-to smoothie: seven scrambled eggs, "a big tub" of cottage cheese, grits, peanut butter, a banana and Gatorade. A daily dose of that concoction added 59 pounds to Bartch's 6-foot-6 frame, helping him morph from a third-string Division III tight end at St. John's (Minnesota) to a fourth-round pick of the Jacksonville Jaguars as an offensive lineman.

"I would just throw it all in and then plug my nose," Bartch said. "In the dark. I would gag sometimes. That's what you have to do sometimes."

Chris Bober, a former New York Giants and Kansas City Chiefs lineman, showed up at the University of Nebraska-Omaha at 225 pounds, which was too small. He ate everything he could get his hands on, which was difficult as a college student "who was pretty broke." It was especially challenging over the summers, when he inherently burned calories at his construction job. If Bober went to Subway, he wouldn't just buy one foot-long sub -- he'd get two. At Taco John's, his order was a 12-pack of tacos and a pound of potato oles, which adds up to a nearly 5,000-calorie lunch.

When Thomas was at Wisconsin, any player trying to gain weight could grab a 10-ounce to-go carton of heavy whipping cream with added sugars and whey protein after a workout. He surmises the dairy-forward drink went for about 1,000 calories a pop -- and he chased it with a 50-gram protein shake on his way to class.

Like Hardwick, Staley -- who went from 215 pounds to 295 at Central Michigan, as he transitioned from tight end to the offensive line -- used to set an alarm for himself every day at 2 a.m. "I had these premade weight-gainer shakes; they were probably 2,000 calories each," Staley said. "I'd wake myself up in the middle of the night, down that, go back to bed."

Although Staley worked with his college strength coach to make sure he was putting on "good weight" -- gaining muscle without unnecessary body fat -- the unnatural eating habits took a toll. "I was bloated for four years straight," Staley said. "You know when you overeat after a really nice dinner at an Italian restaurant, you just eat all these courses and leave feeling gross? That's how I felt the entire time in college."

Staley no longer fit into the clothes he arrived at Central Michigan with but couldn't afford to buy new ones, so he was constantly borrowing from teammates. Most offensive linemen admit they pretty much lived in team-issued sweats. "I'm lucky, in the late 1990s, early 2000s, everything baggy was in style," Gross said. "So from 250 to 300, it wasn't a massive wardrobe change. The waist got big, but elastic drawstrings were my best friend."

The habits continue in the NFL. Many older players credit the 2011 collective bargaining agreement, which banned training camp two-a-days, as a turning point. Before then, it felt like their college days. "If I was doing two-a-days, in the summer in South Carolina, going up against Julius Peppers, I was for sure burning 10,000 calories," Gross said.

So at the end of each day in training camp at Wofford College, Gross counted to 15 one-thousands on the soft-serve machine, then blended that with four cups of whole milk, plus three homemade chocolate cookies (which Gross believes were about 850 calories each) and Hershey's chocolate syrup. "That's all inflammatory foods, like sugar and dairy," he said, "I'm not going to say it's horrible; it was pretty awesome to eat that stuff. But you're putting so much demand on your digestive system. I always had gas. I always had to use the bathroom. I was bloated because I was so full all the time."

There's a common refrain among offensive linemen: If you don't lose weight in your first year out of the league, you're probably not going to lose it.

Four years after retiring, Woody weighed 388 pounds and agreed to appear on NBC's "The Biggest Loser." Instead of heavy lifting and concentrating on explosive bursts, Woody was asked to do longer cardio and train for endurance. "It was totally different from what I had learned to do and had trained to do my entire life," Woody said. "And it was hard. Like, man, it was really tough."

Woody lost 100 pounds on the show -- then gained it all back.

So he just accepted his weight, until this past year, when the 42-year-old renovated his basement into an exercise room. "I wanted to lose weight the right way," Woody said. "In a sustainable way."

NFL's best and worst of the 2010s All-decade: Top player for each teamAFC: East | North | West | SouthNFC: East | North | West | South Inside decade's trends for all 32 teams Best teams and players of the decade

Woody lured in his wife and kids to join his mission. On Sunday nights, they meal prep. And every day Woody goes down to the basement to stay active. His prefers the Peloton bike -- "I hit that hard," he said -- but also uses the row machine, and does "all different types of exercises so I don't get bored." While he still lifts weights, he focuses on lighter options and higher reps. "I'm not putting any weight on my back anymore; I'm not lifting excessive weight to potentially hurt myself," Woody said. "Because that's not the point anymore."

On June 14, Woody tweeted that he was down 50 pounds since March 23 "and my joints are already jumping for joy."

It isn't easy. And for many years, players have felt like they're on their own in their weight-loss journey.

"The NFL doesn't give you any guidance on how to do it," Bober said. "They're just like, 'OK, see ya!' You need to take it upon yourself to figure it out. And as I've gotten older and older, I've noticed it does become more and more difficult to manage if you haven't lost it right away."

Shortly after the last CBA in 2011, the NFL Players Association launched "The Trust," which interim executive director Kelly Mehrtens describes as a VIP concierge service of benefits players can take advantage of as they transition outside of the league. As part of a holistic approach, the Trust invites players to Exos (where they can train, get physical therapy and undergo a nutrition consultation), offers them YMCA memberships and arranges physicals and consultations with specialists at hospitals across the country.

The Trust, Mehrtens explains, is all about figuring out why certain guys transition to their post-playing lives more successfully than others, and how they could help bridge the gap. "These are earned benefits," Mehrtens said. "So we want to make sure guys take advantage of something they've already earned."

Dr. Roberts' Living Heart Foundation, a partner of the NFLPA, does health screenings for former players three times per year. Anyone with a BMI of 35 or over is invited to join a six-month program called The Biggest Loser (although this one isn't televised). So far, roughly 50 players have gone through it. Most are in their 40s, with the oldest participant 80 years old. "It just shows it's never too late to find motivation to reach your goals," lead trainer Erik Beshore said.

Beshore said most who enrolled in The Biggest Loser program are diabetic or pre-diabetic. However, after six months, as they commit to sustainable lifestyle changes, many have gone off their insulin, eliminated their blood pressure medication, gotten better sleep and reported overall better moods.

"It's amazing how many of them can lose the weight all these years later," Roberts said. "But in terms of if they can reverse the damage that may have occurred in the interim period form when they played football at large size to years later, it's hard to quantitate because we don't have long-term data yet."

To slim down, Staley cut out most carbs, besides vegetables. He purged his house of his favorite vice, chips and salsa, and now snacks on raw broccoli and Bitchin' Sauce -- an almond-based vegan dip. Staley said he now eats with purpose and moderation. "In the NFL, I always ate when I was hungry and whatever was available," he said. "If it was salmon, great. If it was frozen pizza, I'd eat that too."

Hawley, who retired in 2018, donated most of his material possessions to charity and has been living out of a van and Airbnb's across the country. He said it was all about reconditioning his brain to eat only until he feels full, and not eating until he can't eat anymore. Intermittent fasting has been a huge tool for the 6-foot-3 Hawley, who is down 60 pounds to 240. He rarely eats breakfast and tries to do one 24-hour fast per week -- eating dinner at 6 or 7 p.m., and then not eating at all until 6 or 7 p.m. the following night. Sometimes he even challenges himself to a 36-hour fast.

Hawley has connected with other ex-big guys, such as Hardwick, whom he met at "Bridge to Success," a NFL-run transition program for retired players.

"But it's not as big of a community as I would like," Hawley said. "I'm actually working on creating an online community for guys. That's one thing I've been missing. I went through my whole life being part of a locker room with a team, and then you get into the real world at 30, and nobody really knows what that experience is like."

Hardwick said he's working on an e-book with a blueprint of his diet plan for people who want to lose weight quickly and keep it off.

Many players interviewed for this story said while they do feel better and like the way they look, rapid weight loss has led to unsightly stretch marks and excess, saggy skin (which one player, wishing to stay anonymous, said he had cosmetically removed). Hardwick and Gross also warn of something that happened to them: They got so obsessed with losing the weight that it went too far.

Hardwick remembers weighing himself after a hot yoga class in January 2015. The scale read 202 pounds. "Great," he thought to himself. "Another 3 pounds, and it will be 199." But then he got a glance of his profile in the mirror, and he didn't recognize himself.

"If the apocalypse came, there was no way I could defend me or my family," he said. Hardwick went home and started binge eating to overcorrect. He has hovered between 220 and 230 since, which he thinks is a healthy weight for him.

Gross experimented for a while. He was vegetarian for a year and then tried the paleo diet. "You don't have any wiggle room when you're playing -- you just have to eat to keep the weight on," he said. "So I thought it was exciting to try different things." Once Gross got down to 250, he noticed an immense pain relief in his feet and ankles, which were swollen his last few years in the league -- but due to weight, not injury.

When Gross began his transformation, he went to Old Navy and bought three pairs of shorts and two polo shirts. He didn't know where his weight loss would lead him, and he didn't want to waste money. Gross got all the way down to 225, but restricting himself to under 2,500 calories a day didn't feel like a sustainable lifestyle. "That was too much," he said. As he gets ready to turn 40 this summer, Gross eats about 3,200 calories a day and is back to lifting weights. He now happily hovers around 240 pounds.

As for Thomas? As his career wound down, he began consulting with Katy Meassick, the Browns' nutritionist, who began educating him on healthier habits. They came up with a post-retirement plan, which Thomas describes as "low-carb or keto diet, with intermittent fasting." He added swimming and biking as cardio, along with yoga.

We made every NFL player a free agent, then asked our 32 NFL Nation reporters to re-draft four rounds of high-impact stars with a five-year Super Bowl window in mind. Which team is the best? Re-drafted NFL rosters: All 128 picks Experts react | Stacking the QBs

Thomas, too, had to recondition his brain to stop eating when he was full. Throughout his football career, he had taught his subconscious to go beyond that point and keep stuffing his face with family-size McDonald's orders and sugary drinks. It's a new kind of discipline. Now every Monday, Thomas and his wife, Annie, will try to fast for 24 hours. Because of his previous line of work, it's not such a hard transition.

"As an offensive lineman, you just do the grunt work forever and you do the crap nobody wants to do -- our position is the Mushroom Club. We're used to being s--- on a truck in a dark room, and everyone expects us to go out and perform for no glory whatsoever," Thomas said.

"And you almost miss that misery. It's almost a weird thing to say, but getting into the fasting world and trying to discipline yourself and do something that is hard, in a weird, sick way, [that's something] I think a lot of offensive linemen get."

The rest is here:
How NFL offensive linemen escape the 5,000-calorie lunch and transform in retirement - ESPN

Philips introduces first-of-a-kind mobile ICUs in India to tackle COVID-19 and other emergencies – GlobeNewswire

Amsterdam, the Netherlands and New Delhi, India Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it introduced first-of-its-kind mobile Intensive Care Units (ICUs) in India. Designed to meet the critical-care requirements of patients, each prefabricated ICU has a capacity of nine beds. The units will be locally manufactured by Philips in India, with each ICU unit capable of being deployed in one day.

India is in the top 5 countries with the highest amount of COVID-19 cases. The countrys healthcare system is under immense pressure as infections spike. Leveraging its clinical, technical and design expertise, Philips has developed new mobile ICUs to address the challenging needs of critical-care services in India. They will be useful to government agencies and health systems looking to rapidly increase ICU capacity and enhance community outreach with the aim to mitigate the impact of natural disasters and pandemics such as the ongoing COVID-19 outbreak.

With a floor area of 1380 square feet (128 square meters), these self-sufficient units only require an on-site electricity and water connection to become operational. Each mobile ICU comes pre-equipped with a state-of-the-art critical-care infrastructure, such as independent patient cubicles, plus anti-bacterial paint and high-end washrooms with a self-disinfection facility to avoid cross contamination. The ICUs can be furnished with a range of medical equipment, including ventilators, defibrillators, a central monitoring station and CPAP (Continuous Positive Airway Pressure) machines, with appropriate supporting infrastructure such as back-up power, oxygen and vacuum supplies.

Aligned with the governments commitment to providing quality and accessible healthcare to Indias population, we are proud to introduce our state-of-the-art mobile ICUs for India, said Daniel Mazon, General Manager Philips India. We believe this solution will help the country to tackle COVID-19 in an effective manner as it enables healthcare institutions to increase their critical-care bed capacities. The solution will also be significant in the long term to address future critical care requirements.

Philips mobile ICU solution will offer great advantage in treatment of isolated patients, in disaster management, and for community outreach, said Mahipal Singh Bhanot, Zonal Director of Fortis Healthcare. Additionally, it will enable streamlining of hospital workflows without the need to change their protocols for infectious patients, while maintaining patient and staff safety. This can be a productive asset to have, especially because it is useful in adding additional beds to hospitals in a much reduced time, which means rapid ramp up of a hospitals bed capacity.

Tele-critical care command centersNext to the mobile ICUs Philips is also offering a dedicated tele-critical care command center solution for the Indian market helping hospitals to improve access to acute care and leverage scarce resources such as trained ICU staff in optimized ways. These highly trained intensivists and intensive care nurses are stationed in a central hub and can connect to and remotely monitor patients in peripheral ICUs on a 24/7 basis through advanced dashboards that bring together vital signs, lab values and predictive analytics. Currently there are 5 major tele-critical care command centers in India and these hubs are connected to up to 700 ICU beds across country with Tier 2, 3 city hospitals.

Philips COVID-19 solutions portfolioPhilips has a comprehensive portfolio of services and solutions which can help to support the delivery of high-quality care to COVID-19 patients. It includes secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the Philips centralized COVID-19 hub.

For further information, please contact:Joost MalthaPhilips Global Press OfficeTel.: +31 6 10 55 8116E-mail: joost.maltha@philips.com

Geetika BangiaPhilips IndiaTel.: +91 981 810 2133E-mail: geetika.bangia@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

See the rest here:
Philips introduces first-of-a-kind mobile ICUs in India to tackle COVID-19 and other emergencies - GlobeNewswire

New Vegan Ice Cream Brand Launches to Fight for Social Justice – VegNews

Vegan ice cream brand JUSTice Cream recently launched in Chicago with plans to donate 100 percent of its profits to grassroots organizations that are fighting for social justice. The woman-led company was founded by Hialy Gutierrez to address social issues such as the misconceptions about veganism, human and environmental exploitation, and food industry practices. JUSTice offers a variety of flavors, each of which supports a particular cause, such as:

JUSTice Cream has so far raised nearly $9,000 through a GoFundMe campaign to help with startup costs, equipment, and supplies. The company is also accepting in-kind donations, such as ice cream equipment or accounting help, to help reduce expenses.

The ice cream brand plans to operate through pop-ups in Chicago this summer and distribute pints through local co-ops and neighborhood markets this fall before offering out-of-state delivery.

Please support independent vegan media and get the very best in news, recipes, travel, beauty, products, and more.Subscribe now to the worlds #1 plant-based magazine!

Read this article:
New Vegan Ice Cream Brand Launches to Fight for Social Justice - VegNews

Vegan Cheese Market New Innovations, Research and Growth Factor till 2028 – Lake Shore Gazette

Thevegan cheese marketis expected to continue its steady growth on account of the growing trend of veganism, coupled with the increasing consumer awareness about the health benefits associated with cholesterol-free vegan cheese consumption. The global vegan cheese market is projected to register 8.6% CAGR during the forecast period 2018-2028, owing to the myriad factors mentioned in the PMR report.

Individuals with a fondness for cheese have shown a reluctance towards veganism, however the growing awareness about the different vegan cheese options and variants available in the market has altered the scenario completely. As veganism has already gone mainstream, and consumers inclination towards cheese is showing no signs of waning, vegan cheese companies have focused on introducing plant-based cheese substitutes, including cream cheese, parmesan, cheddar, ricotta, to name a few. Leading vegan cheese companies are focusing on introducing cost-effective vegan cheese variants to appeal to a wider, cost-sensitive demographic.

Request for Sample Report:https://www.persistencemarketresearch.com/samples/27580

PMR report opines that vegan cheese market has witnessed collective growth in the recent years. It is likely to accelerate further in the forthcoming years, on the back of the growing awareness about the lactose-intolerant conditions, in tandem with a significant shift in eating patterns. The report finds that globally, roughly 75% of the population is lactose intolerant, and suggests that the growing awareness about the potential health impact of dairy products will prompt consumers to shift to plant-based milk products, including vegan cheese, among many other dairy substitutes.

According to the study, the growing animal welfare and environmental concerns associated with dairy product consumption are gravitating consumers towards vegan cheese products. The transition to vegan cheese will further solidify, owing to numerous factors, including growing demand for eco-friendly, animal-free sources of protein, and raising concerns about allergens, antibiotic, and hormone use. Many leading food chains, such as Dominos Pizza, McDonalds have listed vegan food products on their menu to tap the expanding vegan population. The report opines convenience stores as the most common and imperative sales channel for vegan cheese customers, with leading grocery chains such as Aldi and Walmart, offering many exotic plant-based cheeses on shelves.

Request for methodology:https://www.persistencemarketresearch.com/methodology/27580

To capitalize on the growing trend for veganism, vegan cheese companies are introducing novel forms of vegan cheese to move ahead of the increasingly competitive vegan cheese market. With the existing players taking efforts to produce vegan cheese variants with an added nutritional value, the global vegan cheese market is anticipated to witness tremendous changes during the forecast period.

The growing consumption of plant-based products in North America has made the region lucrative for the vegan cheese companies; 200 companies have already entered into the market in the recent three years. Meanwhile, the study opines that vegan cheese consumption accounts for roughly 4-5% of plant-based food consumption globally, with Western Europe and North America being the most lucrative and matured markets, owing to the preference for ready-to-eat snacks.

Read more from the original source:
Vegan Cheese Market New Innovations, Research and Growth Factor till 2028 - Lake Shore Gazette

Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients – BioSpace

SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriads market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

About OptraHEALTH: OptraHEALTH is focused on improving outcomes for consumers and leading Life Sciences and Healthcare organizations by utilizing a next-generation Artificial Intelligence Platform. OptraHEALTHs flagship product GeneFAX is an AI-powered knowledge platform for genetic health and is available as a web plugin or mobile application.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, Prolaris and riskScore are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to implementation of this new technology giving patients access to unparalleled online genetic education and support tools; plans to launch the Gene chatbot for its ForeSight and Prequel prenatal tests and for hereditary cancer testing in oncology later this calendar year; details of the functionality of the Gene chatbot; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read this article:

Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients - BioSpace

Children’s National Medical Center and AWS partner for genome project targeting COVID-19 – SiliconANGLE

Finding vaccines or drugs against COVID-19 is certainly one of the main current objectives of medical research centers worldwide. At Childrens National Medical Center, researchers are deploying technology tools from Amazon Web Services Inc. to combine hundreds of data sets to identify genes that might be targeted to treat many diseases, including COVID-19.

We know that there are a lot of drugs that target different genes,and we are particularly interested in, for example, can we repurpose some of these drugs to treatdifferent types of viruses, including COVID-19? said Wei Li (pictured), principal investigator at the Center for Genetic Medicine Research & Center for Cancer and Immunology Research at Childrens National Medical Center.

Li spoke with Stu Miniman, host of theCUBE, SiliconANGLE Medias livestreaming studio, during the AWS Public Sector Summit event. They discussed how the genome project can help combat COVID-19, as well as the role of AWS technology tools in scientific research. (* Disclosure below.)

The Childrens National Medical Center has been using computational biology and gene editing approaches to understand humangenome and disease, and it is particularly interested in a gene-editingtechnology called CRISPR screening, according to Li, who has a research background in computer science.

This is a fascinating technology because it tells you whether one of the 20,000human genes are connected with some certain disease phenotype in one single experiment, he said. We are tryingto, for example, perform machine-learning and data-mining approaches to find new clues of human diseasefrom the original mix and screening big data.

CRISPR screening and other similar screening methods have been widely used in recent years by several research laboratories to study virus infections, such as those related to HIV, Ebola, influenza and now coronavirus, according to Li. Then, the team at the Childrens National Medical Center had an idea: to connect all the sets of screening data related to these viruses to try to extract new information that cannot be identified in a single study.

Can we identify new patterns or new human genes that are commonly responsible for many different virus types? Or can we find some genes that work only from some certain type of viruses? he asked.

Researchers use AWS technology to process and analyze huge amount of data sets, in addition to creating an integrated database in the cloud, so that research results can be freely accessed around the world. It is estimated that AWS technology can reduce the time to process screening data from months to days, according to Li.

Two major benefits are expected from the outcome of this research project.

The first thing is that we hope to find some genes thatcan be potentially drug targets. So, if there are existing drugs that target the genes, then that would be perfect, because we dont need to do anything about this, he explained. And,in the end, we hope that these drugs can have the broad antiviral activity; that means that these drugs can be potentially used to treat COVID-19 and in the future if theres a new virus coming out.

Watch the complete video interview below, and be sure to check out more of SiliconANGLEs and theCUBEs coverage of the AWS Public Sector Summit event. (* Disclosure: TheCUBE is a paid media partner for the AWS Public Sector Summit Online event. Neither Amazon Web Services Inc., the sponsor for theCUBEs event coverage, nor other sponsors have editorial control over content on theCUBE or SiliconANGLE.)

Show your support for our mission with our one-click subscription to our YouTube channel (below). The more subscribers we have, the more YouTube will suggest relevant enterprise and emerging technology content to you. Thanks!

Support our mission: >>>>>> SUBSCRIBE NOW >>>>>> to our YouTube channel.

Wed also like to tell you about our mission and how you can help us fulfill it. SiliconANGLE Media Inc.s business model is based on the intrinsic value of the content, not advertising. Unlike many online publications, we dont have a paywall or run banner advertising, because we want to keep our journalism open, without influence or the need to chase traffic.The journalism, reporting and commentary onSiliconANGLE along with live, unscripted video from our Silicon Valley studio and globe-trotting video teams attheCUBE take a lot of hard work, time and money. Keeping the quality high requires the support of sponsors who are aligned with our vision of ad-free journalism content.

If you like the reporting, video interviews and other ad-free content here,please take a moment to check out a sample of the video content supported by our sponsors,tweet your support, and keep coming back toSiliconANGLE.

Read this article:

Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE

Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer – BioSpace

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy Mahatme, Sareptas executive vice president, chief financial officer and chief business officer, from the company effective July 10, 2020. The company has commenced a search process to identify the future chief financial officer. During the interim period, the finance and accounting functions will report directly to Sareptas Chief Executive Officer, Doug Ingram, and other departments reporting to Mr. Mahatme will be overseen by members of Sareptas executive committee.

The Sarepta from which Sandy retires is a very different one from the organization he joined as our chief financial officer some eight years ago. And the Sarepta of today a financially solid biotechnology organization with perhaps the industrys deepest and most valuable pipeline of genetic medicine candidates with the potential to extend and improve lives would not have been possible without Sandys business acumen and dedication, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. On behalf of our board of directors and the entire organization, I want to wish Sandy all the best in his next journey and thank him for his invaluable and numerous contributions to our success and for having built a strong team of finance leaders who will continue to perform as he departs.

Said Mr. Mahatme, It has been a privilege to serve as Sareptas CFO and CBO for almost eight years and to have participated in its remarkable transformation and extraordinary growth. Working with this leadership team and our talented colleagues, we have built a strong foundation for Sareptas ongoing success in achieving its goal of changing the lives of patients with rare diseases around the world. Having built a strong team of finance, IT, facilities, manufacturing and business development professionals, I feel confident that this is a good time to transition to other opportunities, knowing that Sarepta is well-positioned to continue to lead the industry.

Sandy will continue to serve on the Board of Directors for Flexion Therapeutics, Inc., Aeglea BioTherapeutics, Inc., and Idorsia Pharmaceuticals Ltd.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking StatementThis press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the search process to identify the future chief financial officer, the reporting structure during the interim period and the performance of the finance team; Sareptas potential to extend and improve lives; Sareptas goal of changing the lives of patients with rare diseases around the world; and Sarepta being well-positioned to continue to lead the industry.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

Here is the original post:

Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - BioSpace

The Future of Medicine Is Bespoke – Fair Observer

There was a time when modern medicine was primitive. There were no antibiotics, so every infection took its own course, leading to decline in health. Hypertension and diabetes were largely untreatable. X-ray was new, and remedies had changed but little from medieval times. No one ever embarked on the goodness of preventative treatment, not to speak of predictive medicine, beyond taking a distasteful cod liver oil capsule.

During the last hundred years, modern medicine has undergone a sea change. Just think of it an ever-expanding repertoire of medicines, high-tech procedures, therapies and reams of clinical data to employ when one gets sick. Yet modern medicine remained (in)complete, notwithstanding the therapeutic advances.

READ MORE

Things are now changing thanks to the integration of all such advances, from how a persons diet interacts with ones unique genetic profile to how environmental pollutants affect our thinking, not to speak of preventative medical approaches in health and wellness. The bigperestroikahas begun, and it is poised to transform health care for a growing number of people in the near future. Welcome to a whole new world of personalized, bespoke medicine.

Personalized medicine is, in essence, tailored or customized medical treatment. It treats while keeping in mind the unique, individual characteristics of each patient, which are as distinct as ones fingerprint or signature. It also includes scientific breakthroughs in our understanding of how a persons unique molecular and genetic profile makes them susceptible to certain illnesses. Personalized medicine expands our ability to envisage medical treatments that would not only be effective but also safe for each patient while excluding treatments that may not provide useful objectives.

Personalized medicine is, in simple terms, the use of new methods of molecular scrutiny. It is keyed to help better manage a patients illness or their genetic tendency toward a particular illness or a group of diseases. In so doing, it aims to achieve optimal therapeutic outcomes by helping both clinicians and patients choose a disease management approach that is likely to work best in the context of the patients unique genetic and environmental summary. In other words, it allows to accurately diagnose diseases and their sub-types while prescribing the best form and dose of medication most suited to the given patient.

Personalized, or precision, medicine is not rocket science it is, in essence, an extension of certain traditional approaches to understanding and treating disease. What jazzed up the therapeutic fulcrum of personalized medicine are tools that are more precise. This is what also offers clinicians better insights for selecting a treatment protocol based on a patients molecular profile. Such a patient-specific methodology, as has been practiced for long in certain complementary and alternative medical (CAM) or integrative approaches, not only curtails harmful side effects but also leads to more successful outcomes, including reduced costs in comparison to the current trial-and-error approach to treatment, which has distressingly come to the fore during these extraordinary and unprecedented times of COVID-19.

It is still early days, but the fact remains that personalized medicine has changed the old ways of how we all thought about, identified and managed health issues. As personalized medicine increasingly bids fair to an exciting journey in terms of clinical research and patient care, its impact will only further expand our understanding of medical technology.

What personalized medicine has done is bring about a paradigm shift in our thinking about people in general and also specifically. We all vary from one another what we eat, what others eat, how we react to stress or experience health issues when exposed to environmental factors. It is agreed that such variations play a role in health and disease. It is also being incrementally accepted that certain natural variations found in our DNA can influence our risk of developing a certain disease and how well we could respond to a particular medicine.

All of us are unique individuals, perhaps with the exemption of identical twins, albeit the genomes are unique in them, too. While we are genetically similar, there are small differences in our DNA that are unique, which also makes us distinctive in terms of health, disease and our response to certain medicinal treatments.

Personalized medicine is poised to tap natural variations found in our genes that may play a role in our risk of getting or not getting certain illnesses, along with numerous external factors, such as our environment, nutrition and exercise. Variations in DNA can, likewise, lead to differences in how medications are absorbed, metabolized and used by the body. The understanding of such genetic variations and their interactions with environmental factors are elements that will help personalized medicine clinicians to produce better diagnostics and drugs, and select much better treatments and dosages based on individual needs not as just fixing a pill or two, as is the present-day conventional medical practice.

It is established that a majority of genes function precisely as intended. This gives rise to proteins that play a significant role in biological processes while allowing or helping an individual to grow, adapt and live in their environment. It is only in certain unusual situations, such as a single mutated or malfunctioning gene, that our apple cart is disturbed. This leads to distinct genetic diseases or syndromes such as sickle cell anemia and cystic fibrosis. In like manner, multiple genes acting together can impact the development of a host of common and complex diseases, including our response to medications used to treat them.

New advances will revolutionize bespoke medical treatment with the inclusion of drug therapy as well as recommendations for lifestyle changes to manage, delay the onset of disease or reduce its impact. Not surprisingly, the emergence of new diagnostic and prognostic tools has already raised our ability to predict likely outcomes of drug therapy. In like manner, the expanded use of biomarkers biological molecules that are associated with a particular disease state has resulted in more focused and targeted drug development.

Molecular testing is being expansively used today to identify breast cancer and colon cancer patients who are likely to benefit from new treatments and to preempt recurrences. A genetic test for an inherited heart condition is helping clinicians to determine which course of treatment would maximize benefit and minimize serious side effects while bringing about curative outcomes.

Such complexities exist for asthma and other disorders too. This is precisely where molecular analysis of biomarkers can help us to identify sub-types within a disease while enabling the clinician to monitor their progression, select appropriate medication, measure treatment outcomes and patients response. Future advances may make biomarkers and other tools affordable and allow clinicians to screen patients for relevant molecular variations prior to prescribing a particular medication.

It is already clear that personalized medicine promises three strategic benefits. In terms of preventative medicine, personalized medicine will improve the ability to identify which individuals are predisposed to develop a particular condition. A better understanding of genetic variations could also help scientists identify new disease subgroups or their associated molecular pathways and design drugs to target them. This could also help select patients for inclusion, or exclusion, in late-stage clinical trials. Finally, it will allow to work out the best dosage schedule or combination of drugs for each individual patient.

Yet not everything is hunky-dory for personalized medicine. Critics of precision medicine believe that the whole idea is too much of overhyped razzmatazz, among other things. Proponents, however, argue that when it comes to managing our own health, most of us are used to the idea of taking a one-size-fits-all approach be it medicines, supplements, diets and diagnoses. This may be wrong.

What works, as they put it, for one may be a gaffe for another. As the award-winning oncologist and medical technology innovator, Dr. David B. Agus, author of the groundbreaking bookThe End of Illness, puts it, each patients individual risk factors are based on ones DNA, the environment and a preventative lifestyle plan in response. He begins with simple, profound pointers: How is your sense of smell? and Is your ring finger longer than your middle finger? He explains with statistics-backed guidelines that moving and walking regularly is mandatory because exercising and then sitting is equivalent to smoking cigarettes, while eating and sleeping at consistent hours is imperative because irregularity causes inflammation.

The inference is obvious: We should all understand our physiology and quiz doctors with the thorough, exploratory frame of mind of a gadget buyer. This holds the key to making medicine truly personal, more humane, effective and safe while keeping in mind the individual in us all as unique and distinctive, the sum of the whole not just the parts.

The views expressed in this article are the authors own and do not necessarily reflect Fair Observers editorial policy.

Read more:

The Future of Medicine Is Bespoke - Fair Observer

Movers & Shakers, July 3 | BioSpace – BioSpace

AVROBIO: On Monday, clinical-stage gene therapy company AVROBIO, headquartered in Massachusetts, announced the appointment of Kim Raineri as chief manufacturing and technology officer.

I am thrilled to join AVROBIO, a leader in lentiviral gene therapy and a true pioneer in driving manufacturing advances that address the gene therapy fields need for faster, more scalable and more automated production, Raineri said. The AVROBIO team has created a state-of-the-art gene therapy platform and is clearly committed to continuous innovation on behalf of the patient communities they strive to serve. I am excited to contribute to that work.

Raineri will be replacing AVROBIO co-founder Kim Warren in the position, who will be retiring at the end of July. Before joining AVROBIO, Raineri served as the vice president of operations for Nikon CeLL Innovation Co.

Scenic Biotech: On Wednesday, Netherlands-based Scenic Biotech announced the appointment of their new chief executive officer. Newly appointed CEO Oscar Izeboud brings more than 20 years of life sciences and finance industry experience.

Prior to joining Scenic, Izeboud served as managing director at NIBC Bank in Amsterdam, where he led its corporate finance and capital markets team with a focus on innovation and growth companies.

Former acting CEO and scientific co-founder Sebastian Nijman takes on the role of chief scientific officer.

Akari Therapeutics: Biopharmaceutical company Akari Therapeutics on Wednesday announced the appointment of Torsten Hombeck as chief financial officer and a member of the company's executive team.

Torsten brings a deep understanding of financial strategy, the capital markets and business development to Akari. We are delighted to have him as a permanent member of Akaris executive leadership team," said Clive Richardson, Chief Executive Officer of Akari Therapeutics. "His appointment comes at a time of significant company opportunity and growth. His business and financial expertise will be instrumental in helping us to further develop the Company."

Hormbeck joins Akari with over 20 years of biopharmaceutical industry experience in financial and strategic planning.

Sarepta Therapeutics: Earlier this week, Cambridge-based Sarepta Therapeutics announced the retirement of Sandy Mahatme, the company's executive vice president, chief financial officer and chief business officer. Mahatme will be leaving the company effective July 10.

The Sarepta from which Sandy retires is a very different one from the organization he joined as our chief financial officer some eight years ago. And the Sarepta of today a financially solid biotechnology organization with perhaps the industrys deepest and most valuable pipeline of genetic medicine candidates with the potential to extend and improve lives would not have been possible without Sandys business acumen and dedication, said Doug Ingram, president and chief executive officer of Sarepta Therapeutics.

Sarepta has launched a search to identify the future chief financial officer.

BioMarin: On June 29, BioMarin, a global biotechnology company, announced a pair of promotions. Brian Mueller was promoted to executive vice president, chief financial officer and Andrea Acosta was promoted to group vice president, chief accounting officer.

Mueller has been with BioMarin since 2002, during which he has taken on roles of increasing responsibility. Acosta has been with BioMarin since 2017 as vice president, corporate controller.

Theravance Biopharma: Dublin-based Theravance Biopharma on Thursday announced the appointment of Deepika Pakianathan to its Board of Directors. Pakianathan serves as a managing member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments.

"We are honored to welcome Dr. Pakianathan to our board of directors," said Rick Winningham, chief executive officer of Theravance. "We believe her vast experience in the biotechnology sector, translating breakthrough science and taking important therapies from pipeline to patients, will further enhance our already talented Board of Directors."

Novavax: On Thursday, Maryland-based Novavax announced the appointment of Frank Czworka as senior vice president, global sales. Czworka will be responsible for leading sales planning and distribution for the company. He brings more than 20 years of biopharmaceutical experience to the company, with his most recent experience being as vice president, global customer enngagement at U.S. Pharmacopeia.

Novavax also announced the promotion of Brian Webb to senior vice president, manufacturing. Webb will be responsible for overseeing antigen manufacturing and supply activities in support of the company's vaccine candidates. Webb has been with Novavax since May 2014.

eGenesis: On Wednesday, Massachusetts-based eGenesis announced that it appointed Peter Hanson as chief operating officer. Hanson will be in charge directing eGenesis' day-to-day organizational and operational activities including production and manufacturing.

Peter is a highly experienced biopharmaceutical executive across multiple disciplines, which will be critical to support our next phase of growth as we integrate production and R&D, said Paul Sekhri, President and Chief Executive Officer of eGenesis. Peters operational leadership and veterinary knowledge will help us accelerate our product development as we move closer to IND filing for human clinical studies. We are very grateful for Kenneth Fans many contributions as our founding COO. I am delighted that he will continue to serve as an advisor to the company.

More:

Movers & Shakers, July 3 | BioSpace - BioSpace

A New Generation of Coronavirus Tests Is Coming. Here’s What to Expect. – The New York Times

Still, the quick tests available now are frequently inaccurate. Although they ensure we can get an answer faster, said Dr. Ibukun Akinboyo, a pediatrician and infectious disease specialist at Duke Universitys School of Medicine, you lose some sensitivity, she said. Its hard to win at both.

Last month, a swab-based point-of-care test called Abbott ID Now made headlines when an analysis found that it might miss infections up to 48 percent of the time, despite being promoted by President Trump as highly accurate.

Sensitivity issues also plague antigen tests, which detect pieces of proteins made by the virus, rather than its genes. Antigen tests have been used to detect other airway infections, such as the flu, in less than an hour, and are easy to manufacture en masse. But the convenience comes at a cost: Unlike genetic material, antigens cant be amplified easily. Some antigen tests, including a few that search for influenza viruses, fail to pick up on active infections around 50 percent of the time.

If a Covid antigen test performs like an influenza antigen test, I dont think they will have much utility, said Dr. David Alland, the director of the Center for Emerging Pathogens at Rutgers New Jersey Medical School. Still, he noted, if improved, they could be very promising.

Even imprecise tests have their place in this pandemic, as long as theyre easy to use and distributed widely enough. Should a test miss someone on Monday, maybe youll get them a day or two later, Dr. Wyllie said.

So far, only two companies have received emergency authorization from the F.D.A. for coronavirus antigen tests. One is Quidel, which is, according to a representative, producing millions of tests each month, many of which have been distributed to urgent care centers and medical clinics in the United States. On Monday, a second firm, Becton Dickinson & Company, also entered the fray with a point-of-care antigen test that can reportedly produce results in 15 minutes. While speedy, both Quidels and BDs tests may produce false negatives between 15 and 20 percent of the time.

Other antigen tests have made headway overseas, and experts estimated that several more will likely seek clearance in the United States in coming months.

More here:

A New Generation of Coronavirus Tests Is Coming. Here's What to Expect. - The New York Times

July: Genome sequencing rare diseases | News and features – University of Bristol

A research programme pioneering the use of whole genome sequencing in the NHS has diagnosed hundreds of patients and discovered new genetic causes of disease.

The project, the results of which were published in the journal Nature, offered whole-genome sequencing as a diagnostic test to patients with rare diseases across an integrated health system, a world first in clinical genomics.

Whole genome sequencing is the technology used by the 100,000 Genomes Project, a service set up by the government which aims to introduce routine genetic diagnostic testing in the NHS. The integration of genetic research with NHS diagnostic systems increases the likelihood that a patient will receive a diagnosis and the chance this will be provided within weeks rather than months.

The multi-centre study, led by researchers at the National Institute for Health Research (NIHR) BioResource together with Genomics England, demonstrates how sequencing the whole genomes of large numbers of individuals in a standardised way can improve the diagnosis and treatment of patients with rare diseases.

The researchers, including experts from the University of Bristol, studied the genomes of groups of patients with similar symptoms, affecting different tissues, such as the brain, eyes, kidney, blood, or the immune system. They identified a genetic diagnosis for 60 per cent of individuals in one group of patients with early loss of vision.

Principal investigators Andrew Mumford, Professor of Haematology, and Moin Saleem, Professor of Paediatric Renal Medicine, led the set-up of the programme and oversaw regional enrolment in the South West. Professor Mumford provided national oversight for blood related disorders, while Professor Saleem managed inherited kidney diseases.

Professor Mumford and researchers in the School of Cellular and Molecular Medicine collaborated with the Bristol NIHR Biomedical Research Centre and the University of Cambridge to develop ways to improve the genetic identification of blood disorders, contributing significantly to the breakthrough diagnostic potential.

Professor Mumford said: This pioneering study illustrates the power of whole genome sequencing for diagnosis of rare human diseases. The approach developed in this research has paved the way for the flagship 100,000 Genomes Project and the introduction of whole genome sequencing into standard NHS care.

Professor Saleem established the UK National Renal Rare Disease Registry, and the national and international NephroS (Nephrotic Syndrome) groups, based within the UK Renal Registry in Bristol. These provided recruitment, essential genetic data, and DNA collection for the study. Researchers in Bristol provided functional and clinical insights leading to the discovery of causative genes relating to kidney disorders.

Professor Saleem said: Rare diseases in their entirety are common, in that there are more than 7,000 different rare diseases in total affecting about 7 per cent of the population. Most have a genetic cause, so this research for the first time brings the most powerful genetic sequencing capabilities to apply across the whole health service, meaning all patients will now have the best possible chance of finding their individual genetic defect.

In the study, funded mainly by the National Institute for Health Research, the entire genomes of almost 10,000 NHS patients with rare diseases were sequenced and searched for genetic causes of their conditions. Previously unobserved genetic differences causing known rare diseases were identified, in addition to genetic differences causing completely new genetic diseases.

The team identified more than 172 million genetic differences in the genomes of the patients, many of which were previously unknown. Most of these genetic differences have no effect on human health, so the researchers used new statistical methods and powerful supercomputers to search for the differences which cause disease a few hundred needles in the haystack.

Using a new analysis method developed specifically for the project, the team identified 95 genes in which rare genetic differences are statistically very likely to be the cause of rare diseases. Genetic differences in at least 79 of these genes have been shown definitively to cause disease.

The team searched for rare genetic differences in almost all of the 3.2 billion DNA letters that make up the genome of each patient. This contrasts with current clinical genomics tests, which usually examine a small fraction of the letters, where genetic differences are thought most likely to cause disease. By searching the entire genome researchers were able to explore the switches and dimmers of the genome the regulatory elements in DNA that control the activity of the thousands of genes.

The team showed that rare differences in these switches and dimmers, rather than disrupting the gene itself, affect whether or not the gene can be switched on at the correct intensity. Identifying genetic changes in regulatory elements that cause rare disease is not possible with the clinical genomics tests currently used by health services worldwide. It is only possible if the whole of the genetic code is analysed for each patient.

Dr Ernest Turro, from the University of Cambridge and the NIHR BioResource, said: We have shown that sequencing the whole genomes of patients with rare diseases routinely within a health system provides a more rapid and sensitive diagnostic service to patients than the previous fragmentary approach, and, simultaneously, it enhances genetics research for the future benefit of patients still waiting for a diagnosis.

"Thanks to the contributions of hundreds of physicians and researchers across the UK and abroad, we were able to study patients in sufficient numbers to identify the causes of even very rare diseases."

Paper:

Whole-genome sequencing of patients with rare diseases in a national health system, by Ernest Turro et alin Nature.

There are thousands of rare diseases and, together, they affect more than three million people in the UK. To tackle this challenge, the NIHR BioResource created a network of 57 NHS hospitals which focus on the care of patients with rare diseases.

Based on the emerging data from the present NIHR BioResource study and other studies by Genomics England, the UK government previously announced that the NHS will offer whole-genome sequencing analysis for all seriously ill children with a suspected genetic disorder, including those with cancer. The sequencing of whole genomes will expand to one million genomes per year by 2024.

Whole-genome sequencing will be phased in nationally for the diagnosis of rare diseases as the standard of care, ensuring equivalent care across the country.

Read the rest here:

July: Genome sequencing rare diseases | News and features - University of Bristol

Dropping Race-Based eGFR Adjustment Gains Traction in US – Medscape

A small number of US health systems, as well as some individual physicians, have begun dropping the African American-specific modifier when recording estimated glomerular filtration rate (eGFR), a measure of renal function.

The move aims to correct a race-based health-access inequity that's been in place for more than two decades, say advocates, while others voice concern that the change threatens over-diagnosis of both chronic and end-stage kidney disease in some patients.

In late June, the Boston-based Massachusetts General Brigham health system stopped noting the race-based modifier when its laboratories reported eGFR, and the leadership sent its staff a message discouraging them from applying the modifier. A similar change in eGFR reporting started on June 1 at the University of Washington health system, UW Medicine, Seattle.

These steps followed what is widely regarded as the first institutional change away from race-based adjustment of eGFR, begun in March 2017 at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and they have come amid a growing movement by some individual US physicians to drop the modifier from their practice.

"Momentum is clearly building," said Nwamaka D. Eneanya, MD, a nephrologist at the University of Pennsylvania in Philadelphia, and lead author of a commentary published a little over a year ago that laid out the case for reconsidering how to calculate eGFR in African Americans (JAMA 2019;322:113-4).

"Many discussions are happening at other [US] academic medical centers," Eneanya added, including the system where she works.

The concept is that the formula used to calculate eGFR systematically underestimates the value in African Americans. Hence, it requires a small but meaningful up-adjustment, which can be traced back to the introduction of the Modification of Diet in Renal Disease (MDRD) study equation in 1999 (Ann Intern Med 1999;130:461-70).

The idea was perpetuated in an improved calculation formula, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) that came out a decade later (Ann Intern Med 2009;150:604-12).

These are the most widely used US approaches to eGFR calculation, with the newer CKD-EPI formula predominating.

The rationale for including a modifier for Blacks in the 2009 formula was for improved accuracy relative to the standard reference measure based on iothalamate clearance.

The data used to develop the CKD-EPI formula showed that Black individuals in the dataset had, on average, GFR levels that were 16% higher than people of other races with the same age, sex, and serum creatinine level, according to a recent commentary (Clin J Am Soc Nephrol2020;CJN.12791019). The first author, Andrew S. Levey, MD, was also lead author of the reports that introduced both the MDRD and CKD-EPI equations.

But the argument withers in the light of both its flimsy lynchpin race assessment and the medical and social consequences of its application, say those who have sought change.

"Race is a social, not a biological, construct and the kidney-function race multiplier ignores the substantial genetic diversity within self-identified Black patients," said Thomas D. Sequist, MD, professor of medicine at Harvard Medical School in Boston and chief patient experience and equity officer for Mass General Brigham, who spearheaded the policy change for that system.

"Do we really believe that the population breaks down into just 'Black' and 'not Black,' as the CKD-EPI equation asks us to believe?" he said in an interview.

"The equation was developed from a few thousand patients, and we now apply it to millions of people using a very imprecise measure race."

"Reporting eGFR by race perpetuates a notion that race is a biologic construct when it's not," agreed Rajnish Mehrotra, MD, a professor and chief of nephrology at the University of Washington in Seattle and leader of the eGFR change within his medical system.

Equally compelling, said Mehrotra, Sequist, and others, are the health inequities that have resulted from routinely raising the eGFR in African Americans.

This has led to "withholding treatment from people longer than needed. We arrived at the conclusion that reporting eGFR by race does more harm than good," Mehrotra said in an interview.

Sequist added: "Researchers across Mass General Brigham have demonstrated that use of these race multipliers can lead to important delays in care for Black patients, such as timely evaluation for kidney transplantation."

"Our main concern is that race correction is creating harm."

Eneanya concurs: "It was never designed to oppress patients, but that's where we are. No one ever thought about the repercussions of using race."

And while the movement to eliminate the race modifier is clearly gaining steam, it's also receiving pushback from those who see benefit from the modification and have concern that its abolition could lead to overestimates of kidney disease severity.

Some clinicians "have a hard time letting the race modifier go," Eneanya noted.

In their 2020 commentary, Levey and co-authors write: "We propose a more cautious approach that maintains and improves accuracy of GFR estimates and avoids disadvantaging any racial group."

Their suggested remedies included full disclosure of use of race, accommodation of people who decline to self-identify themselves that way, shared decision-making, and "mindful" use of cystatin C, an alternative to serum creatinine for calculating eGFR.

The latter is regarded as more precise and accurate than serum creatinine across populations butis often not as readily available to many clinicians. Their article also supported looking for even better and more accessible ways to calculate eGFR.

"In the nephrology community, it's pretty controversial," said Mallika L. Mendu, MD, a nephrologist at Brigham and Women's Hospital in Boston, Massachusetts, who has studied the impact of using the modifier on patient assessment.

Her recent review of Mass General Brigham patients found that close to a third of African Americans would have been reclassified with a more severe form of kidney disease if their eGFR had remained unmodified.

"That raised concerns that by using race adjustment we're potentially leading to less equitable outcomes for African American patients," she said. "I'd rather over diagnose than not diagnose in a timely way."

The research that led to development of the MDRD and CKD-EPI equations "are gold-standard studies" that "saw a real difference," Mendu acknowledged in an interview.

"But the way those studies were run and the way they defined the patients was problematic." Despite that, "many nephrologists" agree with the position taken by Levey and co-authors in their recent commentary, she said.

She added that she stopped using the modifier about a year ago in her own practice , well before the system where she works adopted the same approach.

In one sign of the controversy, a quartet of clinicians affiliated with San Francisco General Hospital (SFGH)recently posted an online petition in which they noted that the race modifier had been eliminated in eGFR reports from the hospital's laboratory in October 2019, but more recently had been slated for reinstitution. "We were deeply distressed to recently discover the intended plan to revert back to race-based eGFR reporting at SFGH," they noted.

The same four clinicians also wrote an opinion piece calling for elimination of the modifier in November 2019 in the San Francisco Examiner.

Controversy will likely linger as the movement to withdraw the race modifier spreads without clear agreement on what to do instead.

Mehrotra said he's received inquiries about his system's experience from clinicians at several US medical centers and systems, and he remains comfortable applying the unadjusted CKD-EPI formula to all adults, an approach he called "sufficient."

Other physicians, like nephrologist Vanessa Grubbs, MD, call for a rapid shift to a cystatin C-based, fully race-neutral method for calculating eGFR, a position she detailed in a recent editorial (Clin J Am Soc Nephrol 2020;CJN.00690120).

And at the University of Pennsylvania, Eneanya continues to use race-adjusted eGFR in her practice despite her misgivings because her institution's leadership has not yet agreed on any changes.

"People have a hard time letting it go because it is so important in clinical care. Getting everyone to come to a consensus takes time," she said.

Eneanya, Sequist, and Mendu have reported no relevant financial relationships. Mehrotra has been a consultant for Baxter Healthcare.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Read more:

Dropping Race-Based eGFR Adjustment Gains Traction in US - Medscape

Male fruit flies’ decline in fertility with age is not only driven by changes in sperm – Mirage News

Infertility is one of the most striking effects of ageing. The impact of ageing on females fertility is more severe and much better understood, but it also affects males. Male reproductive ageing is less researched, but of those studies that do address it, most focus on sperm. However, ejaculate contains more than just sperm. Proteins in the seminal fluid are important for fertility, and in many animals, they have a dramatic effect on female physiology and behaviour. Little is currently known about the impact of male ageing on these proteins, and whether any changes contribute to poorer ejaculates in older males.

To resolve these questions, researchers at the University of Oxfords Department of Zoology conducted experiments in a model organism, the fruit fly, Drosophila melanogaster. This species typically lives for less than five weeks, which means that researchers can very rapidly measure the impact of age on male fertility, and their sperm and seminal fluid proteins. This species is also highly amenable to genetic studies, which allowed the researchers to genetically manipulate male lifespan, to see how this impacted the decline in fertility with age.

Published this week in PNAS are their results which show that both sperm and seminal fluid protein quality and quantity decline with male age, making distinct contributions to declining reproductive performance in older males. However, the relative impacts on sperm and seminal fluid often differ, leading to mismatches between ejaculate components. Despite these differences, experimental extension of male lifespan improved overall ejaculate performance in later life, suggesting that such interventions can delay both male reproductive ageing and death.

Lead author Dr Irem Sepil, from the University of Oxfords Department of Zoology, says: These results highlight that the decline in fertility with male age is not exclusively driven by changes in sperm. The quality and quantity of the seminal fluid proteins also change as males age, and these patterns can differ from the changes seen in sperm, but still impact male reproductive function. However, a manipulation aimed at increasing lifespan also slows down age-related reproductive decline. This means that it is possible that drugs and treatments aimed at promoting healthy ageing could be co-opted to slow down male reproductive ageing.

Going forward, the researchers want to look into the health of offspring. In humans, children of old fathers are more at risk of certain medical disorders, but the mechanisms driving these changes remain unclear. Also, whilst a lifespan-extending genetic manipulation helped fertility in older males, it is not clear whether less invasive treatments, which might be used in human medicine, would work similarly. There is ongoing research to understand how we can increase the healthspan of individuals. The aim is not to live longer but to age healthily, slowing down the onset of age-related diseases such as cancer, Alzheimers and arthritis.

It is important to note that the work described here was on a species of fly. While ageing mechanisms are often similar across animals, to understand whether the patterns are commonly shared, they will need to be examined in other species.

Read the paper in PNAS: https://www.pnas.org/content/early/2020/06/30/2009053117

Original post:

Male fruit flies' decline in fertility with age is not only driven by changes in sperm - Mirage News

In the Future, Lab Mice Will Live in Computer Chips, Not Cages – Medscape

Animal models, especially mice, have given scientists valuable insights into the mechanisms behind countless human diseases. They have been instrumental to the discovery of drug targets, metabolic pathways, and gene function. They've helped to lay bare the basic biochemistry of metabolism, hunger, cognition, and aging. Because mice are, to a certain extent, miniature facsimiles of human anatomy and genetics, science has an array of tools at its disposal to manipulate and visualize their bodily processes in real time, in highly controlled settings.

Wikimedia Commons

But, as the recent Covid-19 pandemic has revealed, science doesn't always have the tools to minimize loss of animal life. As the pandemic took hold and academic research labs across the U.S. shuttered indefinitely, scientists were faced with an unprecedented animal care dilemma. Without the teams of veterinary nurses and technicians who usually attend to the animals daily, many labs were forced to resort to wholesale euthanasia. Some labs sacrificed hundreds of animals, and were criticized harshly for their management of their experimental colonies. Many started to consider more durable, long-term plans for preserving and storing their mouse lines.

In the lab where I work at the University of California, San Francisco, and where for the past two years I've been the designated rodent surgeon, we were asked to euthanize all but our most irreplaceable mice. As new animal researchers, we are trained to sacrifice our mice humanely to give them a dignified death. Returning to lab after the shutdown to find rows of empty racks that once held cages of mice we had worked with for months was a shock, and it was hard to conjure dignity in that moment.

That experience led me to reflect on how we as a research community use animal models in biomedical research, and how we might better use them in the future. And I've become increasingly convinced that the animal model of the future will live not in a cage but in a computer chip: By simulating biological systems rather than experimenting with them, we can make drug development and biomedical research safer, more efficient, and more effective.

This is not to say that researchers' treatment of animals has been haphazard. Research in animal models is highly regulated. These regulations vary in austerity from country to country and institution to institution, but they revolve around a common set of principles known as the "three Rs": Replace the use of animals when possible, reduce the number of animals used per experiment, and refine methods to minimize suffering and improve welfare.

As the recent Covid-19 pandemic has revealed, science doesn't always have the tools to minimize loss of animal life.

A few years ago, when I was a new mouse surgeon, the three Rs were the guiding tenets of a week-long course I took at the Ren Remie Surgical Skills Center in Almere, Netherlands. The center's founder, Ren Remie, advocated for meticulous surgical technique, held to the same standards of sterility and post-operative care as any human surgical procedure. But he was also a proponent of the thinking that longer-term strategies can hasten recovery time from infection and surgical procedures. For instance, Remie and other researchers advocate what's called environmental enrichment, a method that helps animals cope with the inherent stress of being isolated after a surgical procedure or during an experiment. The researchers place toys, nesting material, or other inanimate objects in the cage that allow the mouse to engage with its surroundings, similar to the way it would in the wild. Studies suggest that environmental enrichment may even promote wound healing in rats.

But the success of strategies like environmental enrichment highlights an inherent weakness of the animal research model: An animal's behavior is often extremely sensitive to its environment, in ways that are difficult if not impossible to control. This raises a perennial issue in biomedical research of just how reliably conclusions drawn based on studies in mice can be faithfully applied to human disease treatment. For instance, rodents are housed in groups as a rule, but certain kinds of experiments and treatments require them to be isolated, triggering a stress response that could significantly affect their immune activation. Studies have shown that mice and rats who live with companions fare better against injury, stroke, and even tumor growth than their lonely counterparts. As a result, when mice studies ask questions about human diseases, the housing status of the mouse is often a confounding factor. Even slight variation in the ambient temperature of a mouse's housing room can cause stress responsesthat affect experimental outcomes. This variability is one reason that treatments that seem promising in mice often produce underwhelming outcomes in human clinical trials.

One attractive complement to animal studies that may address some of these shortcomings is in silico, or "on a chip" medicine. In silico models apply computational modeling strategies to genomic data to predict physiological responses to drugs or other stimuli. Although they are far from being able to replicate the full complexity of a living, sentient being, the U.S. Food and Drug Administration has begun consider computer modeling-based strategies to update the cumbersome and costly clinical trial pipeline. Research with in vitro models, which attempt to replicate animal physiology in test-tube style experiments, have also shown promise. These efforts have given birth to projects like the Comprehensive in Vitro Proarrhythmia Assay initiative, which integrates modeling and in vitro strategies to evaluate the potential for new drugs to cause heart rate abnormalities

Likewise, in 2013, the European Commission assembled a consortium of research groups known as the Avicenna Alliance to unify academia and industry around a set of standards for computer modeling in medicine. Based in Belgium but comprised of independent organizations around the world, the goal of the Alliance is to enable virtual clinical trials whose results can be validated by the same kinds of rigorous standards that are applied to traditional clinical trials.

As the Avicenna Alliance envisions them, virtual clinical trials would be based on unique genetic models derived from individual patients, rather than on large, genetically variable sample groups. Conceivably, this could allow a researcher to simulate a patient's unique response to a treatment strategy, capturing the effects of subtle variations in baseline metabolism, bodyweight, or underlying health conditions that might influence the patient's treatment outcomes. It might also significantly reduce the time and expense traditionally required to usher a new drug or medical device from the lab bench to the clinic potentially lowering the barrier to care for large swaths of the population who can't afford the often-astronomical costs of life-saving medications.

In silico clinical trials, if and when they are realized, could also address the long-standing problem of sample bias in drug development. Demographically, clinical trials tend to be disproportionately White and, until recently, overwhelmingly male. They therefore don't fully capture the therapeutic value and potential risks that drugs present to the patients who eventually rely on them. If in silico strategies become widely adopted, they'll hold potential to both increase the efficacy of new drugs and expand access to treatment.

The ethical debate around the use of animals in research has roiled for hundreds of years and will likely continue to do so. But what the Covid-19 outbreak has made clear is that there are severe weaknesses in the current animal model paradigm. As experiments have come to a halt during the coronavirus lockdowns, researchers have been given time to consider new, more sustainable approaches to discovery. Hopefully, we will look beyond the short-term technical challenges that will inevitably accompany the resumption of business as usual and gaze further afield, toward more humane, more modernized approaches to doing science.

Lindsay Gray is a lab manager at the University of California, San Francisco.

See the rest here:

In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Medscape

CMU team evaluates range and battery tradeoffs between vehicle automation and electrification – Green Car Congress

A team of researchers at Carnegie Mellon University (CMU) has used a vehicle dynamics model to evaluate the trade-off between automation and electric vehicle range and battery longevity. The researchers compared vehicle-level energy use, range and battery life of a vehicle equipped to attain Society of Automotive Engineers (SAE) levels 45 automation to human-driven EVs by undertaking a careful consideration of the effect on vehicle-level energy use of the different components needed for automated driving, as well as the potential increase in drag from LiDAR (light detection and ranging).

They found that automation will likely reduce electric vehicle range by 510% for suburban driving and by 1015% for city driving. The effect on range is strongly influenced by sensor drag for suburban driving and computing loads for city driving. They also found that the impact of automation on battery longevity is negligible. Their paper is published in Nature Energy.

Box plot showing the range impact for the composite drive profile and for automated solutions with and without LiDAR. The y axis shows the percentage change in range for the AEVcompared to the base EV. The horizontal red line is the median change in range, and the red data points are the data that are beyond the whisker where the maximum whisker length is 1.5 times theinterquartile range. The x axis lists the five EVs considered in the analysis. Mohan et al.

While some commentators have suggested that the power and energy requirements of automation mean that the first automated vehicles will be gaselectric hybrids, our results suggest that this need not be the case if automakers can implement energy-efficient computing and aerodynamic sensor stacks.

Mohan et al.

Two of the researchers had developed a physics-based vehicle dynamics model to estimate the energy demands of an EV given a realistic driving profile. Using a realistic velocity profile with a 1 s temporal resolution the model calculates the instantaneous power needed each second to overcome vehicle inertia, aerodynamic drag and road friction.

The CMU team extended the model for autonomous electric vehicles (AEVs) by adding the weight of the different components to the mass of the vehicle and battery pack, and increasing the drag coefficient for automated solutions with a roof-based spinning LiDAR.

If no LiDAR is used, or if solid-state LiDAR that is incorporated into the aerodynamic profile of the vehicle is used, the increase in drag is zero. They also modified the velocity profile to account for potentially smoother driving and add the computing and sensor loads at each second.

Keeping track of the total energy used, they repeated the driving profile until the battery was fully depleted. They then compared the resulting range estimates for a given battery capacity to conventional EVs.

All underlying data are publicly available at https://github.com/battmodels/Automation-EV-Range. Source data are provided with the paper.

Resources

Mohan, A., Sripad, S., Vaishnav, P. et al. (2020) Trade-offs between automation and light vehicle electrification. Nat Energy doi: 10.1038/s41560-020-0644-3

Read the rest here:

CMU team evaluates range and battery tradeoffs between vehicle automation and electrification - Green Car Congress